142 related articles for article (PubMed ID: 3884114)
1. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis.
Gordon PA; Carroll DJ; Etches WS; Jeffrey V; Marsh L; Morrice BL; Olmstead D; Warren KG
Can J Neurol Sci; 1985 Feb; 12(1):39-44. PubMed ID: 3884114
[TBL] [Abstract][Full Text] [Related]
2. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Lancet; 1991 Feb; 337(8739):441-6. PubMed ID: 1671468
[TBL] [Abstract][Full Text] [Related]
3. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis.
Weiner HL; Dau PC; Khatri BO; Petajan JH; Birnbaum G; McQuillen MP; Fosburg MT; Feldstein M; Orav EJ
Neurology; 1989 Sep; 39(9):1143-9. PubMed ID: 2549450
[TBL] [Abstract][Full Text] [Related]
4. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.
Noseworthy JH; Ebers GC; Vandervoort MK; Farquhar RE; Yetisir E; Roberts R
Neurology; 1994 Jan; 44(1):16-20. PubMed ID: 8290055
[TBL] [Abstract][Full Text] [Related]
5. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
[TBL] [Abstract][Full Text] [Related]
6. Plasma exchange in multiple sclerosis.
Guarnieri BM; Capparelli R; Fratiglioni L; Inzitari D; Sità D; Amaducci L; Avanzi G; Biani D; Franco C; Lombardo R
Int J Artif Organs; 1985 Jul; 8(4):215-20. PubMed ID: 3902665
[No Abstract] [Full Text] [Related]
7. Azathioprine in multiple sclerosis: the cons.
Silberberg DH
Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
[TBL] [Abstract][Full Text] [Related]
8. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone.
Tindall RS; Walker JE; Ehle AL; Near L; Rollins J; Becker D
Neurology; 1982 Jul; 32(7):739-43. PubMed ID: 7201110
[TBL] [Abstract][Full Text] [Related]
9. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.
Lancet; 1988 Jul; 2(8604):179-83. PubMed ID: 2899660
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis.
Brochet B; Deloire M; Germain C; Ouallet JC; Wittkop L; Dulau C; Perez P; Thevenot F; De Sèze J; Zéphir H; Vermersch P; Pittion S; Debouverie M; Laplaud DA; Clavelou P; Ruet A
J Clin Apher; 2020 Aug; 35(4):281-289. PubMed ID: 32369661
[TBL] [Abstract][Full Text] [Related]
11. Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis.
Cook SD; Devereux C; Troiano R; Wolansky L; Guarnaccia J; Haffty B; Bansil S; Goldstein J; Sheffet A; Zito G; Jotkowitz A; Boos J; Dowling P; Rohowsky-Kochan C; Volmer T
J Neurol Sci; 1997 Nov; 152(2):172-81. PubMed ID: 9415539
[TBL] [Abstract][Full Text] [Related]
12. Immunoadsorption (IA) versus plasma exchange (PE) in multiple sclerosis--first results of a double blind controlled trial.
Schmitt E; Behm E; Buddenhagen F; Ernst B; Hitzschke B; Kracht M; Korten G; Kundt G; Meyer-Rienecker H; Osten B
Prog Clin Biol Res; 1990; 337():289-92. PubMed ID: 2191322
[No Abstract] [Full Text] [Related]
13. Immunological treatment of multiple sclerosis. II.
Hughes RA
J Neurol; 1986 Apr; 233(2):66-8. PubMed ID: 3009722
[No Abstract] [Full Text] [Related]
14. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group.
Cole E; Cattran D; Magil A; Greenwood C; Churchill D; Sutton D; Clark W; Morrin P; Posen G; Bernstein K
Am J Kidney Dis; 1992 Sep; 20(3):261-9. PubMed ID: 1519607
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
16. The Mayo Clinic experience with plasma exchange in chronic inflammatory-demyelinating polyneuropathy (CIDP).
Dyck PJ; Pineda A; Swanson C; Low P; Windebank A; Daube J
Prog Clin Biol Res; 1982; 106():197-204. PubMed ID: 6757940
[TBL] [Abstract][Full Text] [Related]
17. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article].
Noseworthy JH; Ebers GC; Vandervoort MK; Farquhar RE; Yetisir E; Roberts R
Neurology; 2001 Dec; 57(12 Suppl 5):S31-5. PubMed ID: 11902593
[No Abstract] [Full Text] [Related]
18. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs.
Khatri BO; McQuillen MP; Harrington GJ; Schmoll D; Hoffmann RG
Neurology; 1985 Mar; 35(3):312-9. PubMed ID: 3974889
[TBL] [Abstract][Full Text] [Related]
19. An assessment of plasma exchange in progressive multiple sclerosis.
Weiner HL
Neurology; 1985 Mar; 35(3):320-2. PubMed ID: 3883234
[No Abstract] [Full Text] [Related]
20. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.
Milanese C; La Mantia L; Salmaggi A; Campi A; Bortolami C; Tajoli L; Nespolo A; Corridori F
Ital J Neurol Sci; 1988 Feb; 9(1):53-7. PubMed ID: 3281916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
